drugset / Trial / NCT04095182
Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian Adult
RandomizedSequentialDouble-blindTreatment
Summary
A dose randomized, double-blind, placebo controlled, single and multiple dosing, dose-escalation phase I clinical trial to investigate the safety, tolerability and pharmacokinetic characteristics of Zebinix (Eslicarbazepine acetate) after oral administration in healthy Korean and Caucasian adult subjects
Timeline
- Start
- 2019-08-22
- Primary completion
- 2019-12-16
- Completion
- 2019-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eslicarbazepine acetate | Unknown | 400 mg | Oral |
| Subject | Eslicarbazepine acetate | Unknown | 800 mg | Oral |
| Subject | Eslicarbazepine acetate | Unknown | 1600 mg | Oral |